Poxel S.A. (0RA2) is a Biotechnology company in the Healthcare sector, listed on London Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Poxel S.A. in 2026. The next earnings report is expected on September 23, 2026.
Next earnings date
23 Sep 2026
In 34 days
EPS estimate
—
Revenue estimate
—
Past earnings
Latest earnings analysis
Missed consensus estimates cannot be determined for Poxel S.A.'s latest earnings, as EPS was not disclosed while revenue totaled usd 1.24 million. There is no previous report available to indicate whether EPS or revenue had been ahead of or below expectations.
No dividend history available.
Poxel S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to discovering innovative therapies for metabolic disorders, particularly type 2 diabetes and various liver conditions. Its primary asset, TWYMEEG (Imeglimin), is an oral medication that addresses mitochondrial dysfunction and has already received approval in Japan for managing type 2 diabetes. Poxel is also advancing PXL770, an activator of the adenosine monophosphate-activated protein kinase (AMPK) enzyme, currently in Phase 2a trials for various chronic metabolic diseases, notably liver ailments like non-alcoholic steatohepatitis (NASH). Furthermore, the company holds licensing agreements: one with Enyo Pharma S.A.S. for a farnesoid X receptor (FXR) agonist, now in a Phase 2a study for hepatitis B and NASH, and another with DeuteRx LLC for PXL065, a mitochondrial pyruvate carrier inhibitor undergoing Phase 1 evaluation specifically for NASH treatment. Established in 2009, Poxel S.A. operates from its headquarters in Lyon, France.
Poxel S.A. (0RA2) is scheduled to report earnings on September 23, 2026.
Poxel S.A. (0RA2) last reported earnings on December 9, 2024.
Poxel S.A. (0RA2) is listed on London Exchange.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.